Ironwood Pharmaceuticals: Strong revenue outlook for 2026 shifts focus back to Linzess!

At the beginning of the year, the stock of Ironwood Pharmaceuticals recorded a significant increase in price. The reason: Ironwood Pharmaceuticals has presented a surprisingly high revenue outlook for 2026. After a stock price decline of around 70% in 2024 and 2025, investors reacted enthusiastically to the new forecast, as it is significantly higher than previous market expectations. After recent developments in the pipeline disappointed, the focus is now shifting to the drug Linzess. New revenue forecast more than 50% above previous consensus...